Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of concurrent TP53 mutations on the efficacy and prognosis of targeted therapy for advanced EGFR mutant lung adenocarcinoma.

Cancer genetics - 1 Nov 2023

Qian Huiwen, Hou Chunqi, Zhang Yi, Ji Shundong, Zhong Chongke, Li Juan, Zhang Qianqian, Huang Jianan, Li Chong, ChengJi

Abstract excerpt

BACKGROUND: How concurrent TP53 mutations affect targeted therapy of advanced Epidermal Growth Factor Receptor (EGFR) mutant lung adenocarcinoma remains controversial, particularly the deep classification of TP53 mutations. METHODS: This study retrospectively analyzed the clinical data of advanced EGFR mutant lung adenocarcinoma patients treated with EGFR-tyrosine kinase inhibitors (TKIs) in the First Affiliated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Prognosis

Share to Protein Kinase Inhibitors

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 37672936
DOI: 10.1016/j.cancergen.2023.08.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of concurrent TP53 mutations on the efficacy and prognosis of targeted therapy for advanced EGFR mutant lung adenocarcinoma.PMID 37672936Read ↗

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysisSemantic proximity Read ↗

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.Semantic proximity Read ↗

Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLCSemantic proximity Read ↗

[Research Advances of EGFR-TP53 Co-mutation in Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

TP53 Co-Mutations in Advanced EGFR-Mutated Non–Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer TherapySemantic proximity Read ↗

[The influence of TP53 mutation on the therapeutic effect of EGFR tyrosine kinase inhibitor and prognosis of EGFR mutant non-small cell lung cancer patients].Semantic proximity Read ↗

The clinical features and prognostic implications of the co-mutated TP53 gene in advanced non-small cell lung cancer.Semantic proximity Read ↗

Effects of Tp53 Gene Mutations on the Survival of Non-Small Cell Lung Cancer (NSCLC); A Short ReviewSemantic proximity Read ↗

The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.Semantic proximity Read ↗

Mutation patterns and evolutionary action score of TP53 enable identification of a patient population with poor prognosis in advanced non-small cell lung cancer.Semantic proximity Read ↗

Effect of EGFR-TP53 co-mutation on the efficacy of EGFR-TKIs in patients with advanced NSCLC and therapeutic strategies: A retrospective study.Semantic proximity Read ↗

Impact of TP53 Mutations on EGFR-Tyrosine Kinase Inhibitor Efficacy and Potential Treatment Strategy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.